January 20, 2017 04:14 PM EST

After repeated setbacks on the checkpoint front, Bristol-Myers scores a $625M payout from Merck to settle patent fracas

John Carroll

Editor & Founder

Bristol-Myers Squibb may keep losing to Keytruda on key franchise initiatives, but at least now it can share in Merck’s good fortunes. Bristol-Myers and Ono …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After repeated setbacks on the checkpoint front, Bristol-Myers scores a $625M payout from Merck to settle patent fracas

John Carroll

Editor & Founder

Sign up to read this article for free.

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas

Halozyme withdraws Evotec acquisition proposal after biotech is 'unwilling to engage'

Are programs with compounded GLP-1s safe for your population?

Af­ter re­peat­ed set­backs on the check­point front, Bris­tol-My­ers scores a $625M pay­out from Mer­ck to set­tle patent fra­cas

John Carroll

Editor & Founder

Sign up to read this article for free.

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

After repeated setbacks on the checkpoint front, Bristol-Myers scores a $625M payout from Merck to settle patent fracas

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas

Halozyme withdraws Evotec acquisition proposal after biotech is 'unwilling to engage'

Are programs with compounded GLP-1s safe for your population?